Wockhardt Limited has scheduled an investor meet for June 4, 2026, to provide a strategic overview of its operations. The meeting will be held at the Atrium, NSE Exchange Plaza, Bandra Kurla Complex (BKC), Mumbai, commencing at 4:00 PM IST. The event is being conducted pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The agenda features presentations by key members of the management team. Dr. Murtaza Khorakiwala will deliver a strategic overview presentation, followed by specific business updates. Ms. Zahabiya Khorakiwala will present on the Zaynich US business, while Ms. Annapurna Das will cover the Zaynich India business. The session will also include film presentations.

A question-and-answer discussion is scheduled for 5:00 PM IST. This session will be attended by Founder Chairman Dr. Habil Khorakiwala, along with Dr. Murtaza Khorakiwala, Ms. Zahabiya Khorakiwala, Ms. Annapurna Das, Dr. Mahesh Patel, and Dr. Sachin Bhagwat.

Investors wishing to raise specific questions may email them to investorrelations@wockhardt.com by June 3, 2026. Alternatively, queries can be raised during the meet. Registration for in-person attendance will close at 11:00 AM IST on June 4, 2026.

Schedule of Events

Wockhardt Limited announced on May 30, 2026, that it has received approval from the U.S. Food and Drug Administration (FDA) for ZAYNICH™ (cefepime and zidebactam). This novel intravenous antibiotic is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis. This approval marks a significant milestone as ZAYNICH™ is the first New Chemical Entity fully developed and commercialized by an Indian pharmaceutical company to receive FDA approval.

Clinical Efficacy and Trial Results

The FDA approval was based on the results of the Phase 3 ENHANCE-1 clinical trial. ZAYNICH™ demonstrated superior efficacy compared to meropenem, achieving a composite clinical cure and microbiological response rate of 89.0% versus 68.4% for meropenem. The treatment difference was 20.6% (95% CI; 12.3, 29.5). The randomized, double-blind, multicenter study enrolled 530 patients across 64 sites in the U.S., Europe, LATAM, China, and India. The drug was generally well tolerated during the study.

Mechanism of Action and Designations

ZAYNICH™ is a multi-penicillin-binding protein targeting combination of the 4th generation cephalosporin cefepime and zidebactam. Unlike most other beta-lactam combinations, it targets multiple penicillin binding proteins (PBP 1a/b, 2 and 3) simultaneously. This mechanism provides bactericidal activity against challenging drug-resistant Gram-negative bacteria. The drug previously received Qualified Infectious Disease Product (QIDP), Fast Track, and Priority Review designations from the FDA.

Regulatory and Strategic Milestones

Dr. Habil F. Khorakiwala, Founder and Chairman of Wockhardt Group, highlighted that this approval represents a historic milestone for the Indian pharmaceutical industry. Prior to the U.S. approval, ZAYNICH™ was approved by the Drugs Controller General of India (DCGI) on May 27, 2026. Wockhardt has also submitted a Marketing Authorization Application (MAA) to the European Medicines Agency. The company currently has a pipeline of six antibiotics, all granted QIDP designation by the U.S. FDA.